Page 18 - கூட்டணி க்கு பெருவாரியாக பரவும் தொற்று நோய் ப்ரிப்யாரெட்நெஸ் கண்டுபிடிப்பு News Today : Breaking News, Live Updates & Top Stories | Vimarsana
COVID-19 vaccine 89.3% effective in U.K. trial but less so in South Africa, Novavax says Sorry, but your browser needs Javascript to use this site. If you re not sure how to activate it, please refer to this site: https://www.enable-javascript.com/
A volunteer in Novavax’s South Africa trial is examined by a doctor before receiving an injection at Wits RHI Shandukani Research Centre, in Johannesburg, in December. | JOAO SILVA / THE NEW YORK TIMES
Reuters Jan 29, 2021
Chicago – Novavax Inc said Thursday its novel coronavirus vaccine was 89.3% effective in preventing COVID-19 in a trial conducted in the United Kingdom, and was nearly as effective in protecting against the more highly contagious variant first discovered in the country, according to a preliminary analysis.
Serum Institute seeks approval to conduct trial for Novavax COVID-19 vaccine
Last year in September, Novavax had announced its deal with Serum Institute in order to produce 2 billion doses of COVID-19 vaccines
BusinessToday.In | January 29, 2021 | Updated 16:49 IST
Novavax s protein-based coronavirus vaccine was 89.3 per cent effective in preventing coronavirus in a trial conducted in the UK
After successfully manufacturing the University of Oxford-AstraZeneca s Covishield vaccine in India, Serum Institute of India (SII) has now applied to India s drug controller to conduct a trial of Novavax Inc s COVID-19 vaccine. Serum Institute s CEO Adar Poonwalla told news agency Reuters that he is expecting a decision on the Indian trial on Novavax s vaccine soon.
Novavax vaccine 89 per cent effective in British trial
Julie Steenhuysen
Save
Share
Chicago | Novavax said on Thursday (Friday AEST) that its coronavirus vaccine was 89.3 per cent effective in preventing COVID-19 in a trial conducted in Britain, and was nearly as effective in protecting against the more highly contagious variant discovered there, according to a preliminary analysis.
A mid-stage trial of the vaccine in South Africa, where a troubling new variant of the virus is common, showed 60 per cent effectiveness among people who did not have HIV.
Novavax said the trial, which enrolled 15,000 people aged 18 to 84, was expected to be used to apply for regulatory review in Britain.Â
The Brazilian National Council for Scientific and Technological Development (CNPq) recently announced a list of research projects selected in a call for proposals to receive R$50 million in funding for COVID-19 research. Of this amount, R$30 million will be drawn from the National Fund for Scientific and Technological Development (FNDCT) for research into treatments, vaccines, diagnostic tests, and the pathogenesis or biological mechanism of the disease. The other R$20 million will be contributed by the Brazilian Ministry of Health for use in projects around prevention, containment and healthcare (
see article). The overwhelming response to the call for projects shows that the scientific community in Brazil is eager to advance research about the disease, more than the government can afford. A total of 2,219 project proposals were submitted. If all were approved, these projects would involve R$1.7 billion in funding, 34 times more than available. An evaluation committee recommended a